Achieving Energy Balance: Aspiration…Inspiration…Motivation…Implementation! Julie Louise Gerberding, M.D., M.P.H
Director
Centers for Disease Control and Prevention (CDC)
Administrator
Agency for Toxic Substances and Disease Registry
Thursday, September 16, 2004
1:00 p.m. to 2:00 p.m.
Masur Auditorium, Clinical Center
National Institutes of Health
Dr. Julie Louise Gerberding, Director of the Centers for Disease Control and Prevention, will talk about how CDC is working on many levels across various disciplines to reverse the disturbing trends in the nation's obesity epidemic. She will also discuss CDC's new research initiatives and the need for increased collaboration among government agencies, industry, and other partners.
About the Speaker
Dr. Julie Louise Gerberding, M.D., M.P.H., became the Director of the Centers
for Disease Control and Prevention (CDC) and the Administrator of the Agency
for Toxic Substances and Disease Registry (ATSDR) on July 3, 2002. Before
becoming CDC Director and ATSDR Administrator, Dr. Gerberding was Acting Deputy
Director of the National Center for Infectious Diseases (NCID), where she
played a major role in leading CDC's response to the anthrax bioterrorism
events of 2001. She joined CDC in 1998 as Director of the Division of
Healthcare Quality Promotion, NCID, where she developed CDC's patient safety
initiatives and other programs to prevent infections, antimicrobial resistance,
and medical errors in healthcare settings. Prior to joining CDC, Dr. Gerberding
was a University of California at San Francisco (UCSF) faculty member and
directed the Prevention Epicenter, a multidisciplinary research, training, and
clinical service program that focused on preventing infections in patients and
their healthcare providers. Dr. Gerberding is an Associate Clinical Professor
of Medicine (Infectious Diseases) at Emory University and an Associate
Professor of Medicine (Infectious Diseases) at UCSF. She earned a B.A. magna
cum laude in chemistry and biology and an M.D. at Case Western Reserve
University in Cleveland, Ohio. Dr. Gerberding then completed her internship and
residency in internal medicine at UCSF, where she also served as Chief Medical
Resident before completing her fellowship in Clinical Pharmacology and
Infectious Diseases at UCSF. She earned an M.P.H. degree at the University of
California, Berkeley in 1990.
Dr. Gerberding is a member of Phi Beta Kappa, Alpha Omega Alpha (medical honor
society), American Society for Clinical Investigation (ASCI), American College
of Physicians, the American Epidemiology Society, and is a Fellow in the
Infectious Diseases Society of America (IDSA). She chaired and co-chaired
IDSA's Committee on Professional Development and Diversity, was elected to
serve as a member of the Nominations Committee, and co-chaired the Annual
Program Committee. Dr. Gerberding is a member of the Society for Healthcare
Epidemiology of America, and previously served on its board for 3 years.
In the past, Dr. Gerberding served as a member of CDC's National Center for
Infectious Diseases' Board of Scientific Counselors, the CDC HIV Advisory
Committee, and the Scientific Program Committee, National Conference on Human
Retroviruses. She has also been a consultant to the National Institutes of
Health, the American Medical Association, CDC, the Occupational Safety and
Health Administration, the National AIDS Commission, the Congressional Office
of Technology Assessment, and the World Health Organization.
Dr. Gerberding's editorial activities include appointment to the Editorial
Board of the Annals of Internal Medicine. She is also an Associate Editor of
the American Journal of Medicine, and serves as a peer-reviewer for numerous
internal medicine, infectious diseases, and epidemiology journals. Her
scientific interests encompass patient safety and prevention of infections and
antimicrobial resistance among patients and their healthcare providers. She has
authored or co-authored more than 140 peer-reviewed publications and textbook
chapters and contributed to numerous guidelines and policies relevant to HIV
prevention, post-exposure prophylaxis, management of infected healthcare
personnel, and healthcare-associated infection prevention.
Back to Top |